<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00551694</url>
  </required_header>
  <id_info>
    <org_study_id>HMA110541</org_study_id>
    <nct_id>NCT00551694</nct_id>
  </id_info>
  <brief_title>A Second Study to Determine the Effect of GSK256073A on HVTs</brief_title>
  <official_title>A Second Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single and a Repeat Oral Dose of GSK256073A in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects of single and repeat doses of GSK256073&#xD;
      with placebo in HVT subjects that have been administrated GSK256073 in the HMA107787 study&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AEs, 12-Lead ECG, vital signs, nursing/physician observation, safety lab tests, flushing throughout the study.</measure>
    <time_frame>throughout the study.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC and Cmax</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measures of accumulation ratios throughout the study (Ro, Rp, and Rs)[Period 2]</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax, t½, Ae, and CLr , Cmax, ss, Ct, t½, Ae, CLr, and accumulation ratios throughout the study</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD response: NEFA and TG (6 and 24 hours post- dose), LDL, HDL, ApoA1, ApoA2, Apo B and Lp(a) on Days 1, 14, and 15.</measure>
    <time_frame>Days 1, 14, and 15</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">4</enrollment>
  <condition>Healthy Subjects</condition>
  <condition>Dyslipidaemias</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK256073A tablets</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy as determined by a responsible physician, based on a medical evaluation&#xD;
             including history, physical examination, laboratory tests, cardiac monitoring. A&#xD;
             subject with a clinical abnormality or laboratory parameters outside the reference&#xD;
             range for the population being studied may be included only if the Investigator&#xD;
             considers that the finding will not introduce additional risk factors and will not&#xD;
             interfere with the study procedures&#xD;
&#xD;
          -  Healthy adult males or females between 18 and 55 years of age, inclusive.&#xD;
&#xD;
          -  Female subjects must be of non-childbearing potential including pre-menopausal females&#xD;
             with documented (medical report verification) hysterectomy or double oophorectomy or&#xD;
             postmenopausal defined as 12 months of spontaneous amenorrhea or 6 months of&#xD;
             spontaneous amenorrhea with serum FSH levels &gt; 40 mIU/mL or 6 weeks postsurgical&#xD;
             bilateral oophorectomy with or without hysterectomy, or documented hysterectomy -&#xD;
             tubal ligation is not sufficient&#xD;
&#xD;
          -  Body weight &gt; 50 kg (110 pounds) and body mass index (BMI) between 19 and 31 where:&#xD;
&#xD;
          -  Subjects with QTc &lt; 450 msec at screening (or QTc &lt; 480 msec for subjects with Bundle&#xD;
             Branch Block).&#xD;
&#xD;
          -  A signed and dated written informed consent prior to admission to the study&#xD;
&#xD;
          -  The subject is able to understand and comply with protocol requirements, instructions&#xD;
             and protocol-stated restrictions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically relevant abnormality identified on the screening medical assessment,&#xD;
             laboratory examination or ECG&#xD;
&#xD;
          -  Systolic blood pressure &lt; 100 mmHg or ≥ 140 mmHg and/or diastolic blood pressure ≥ 90&#xD;
             mmHg at the screening visit&#xD;
&#xD;
          -  History of significant cardiac arrhythmias.&#xD;
&#xD;
          -  Active peptic ulcer disease (PUD) and/or history of PUD&#xD;
&#xD;
          -  Screening test positive for H. pylori at the screening visit&#xD;
&#xD;
          -  History of gout and/or hyperuricemia&#xD;
&#xD;
          -  A serum creatinine concentration above the reference range&#xD;
&#xD;
          -  History of kidney stones&#xD;
&#xD;
          -  PT and/or aPTT above the reference range&#xD;
&#xD;
          -  History of recurrent indigestion, stomach upset or diarrhea&#xD;
&#xD;
          -  Liver function tests (LFTs) or creatinine phosphokinase (CPK) above the normal&#xD;
             reference range&#xD;
&#xD;
          -  Positive HIV, Hepatitis B surface antigen or Hepatitis C antibody within 3 months of&#xD;
             screening&#xD;
&#xD;
          -  Positive urine drug and alcohol screen at screening or predose on Day 1 of each period&#xD;
&#xD;
          -  History of alcohol consumption exceeding, on average, 7 drinks/week for women or 14&#xD;
             drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of&#xD;
             hard liquor) within 6 months of the first dose of study medication or a positive&#xD;
             alcohol test at screening&#xD;
&#xD;
          -  History of use of tobacco or nicotine containing products within 6 months of screening&#xD;
             or a positive urine cotinine screen&#xD;
&#xD;
          -  Use of antimicrobials, proton pump inhibitors and bismuth containing medications&#xD;
             within 2 weeks prior to testing for H. pylori at Screening&#xD;
&#xD;
          -  Use of prescription (including hormone replacement therapy) or non-prescription drugs&#xD;
             and vitamins within 7 days or 5 half-lives (whichever is longer) prior to&#xD;
             administration of study medication. Use of prescription antibiotics within 14 days&#xD;
             prior to administration of study medication. An exception is acetaminophen which is&#xD;
             allowed at doses of &lt; 2g/day&#xD;
&#xD;
          -  Use of dietary/herbal supplements including (but not limited to) St. John's wort,&#xD;
             kava, ephedra (ma huang), gingko biloba, DHEA, yohimbe, saw palmetto, ginseng and red&#xD;
             yeast rice within 14 days prior to treatment with study medication&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received a drug or a new&#xD;
             chemical entity within 30 days or 5 half-lives, or twice the duration of the&#xD;
             biological effect of any drug(whichever is longer) prior to the first dose of current&#xD;
             study medication&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the physician responsible,&#xD;
             contraindicates their participation&#xD;
&#xD;
          -  Consumption of grapefruit or grapefruit juice within 7 days prior to the first dose of&#xD;
             study medication&#xD;
&#xD;
          -  Donation of blood in excess of 500 mL within 56 days prior to dosing&#xD;
&#xD;
          -  Unwillingness of male subjects to use a condom/spermicide, in addition to having their&#xD;
             female partner use another form of contraception, such as an IUD, diaphragm with&#xD;
             spermicide, oral contraceptives, injectable progesterone, subdermal implants or a&#xD;
             tubal ligation, if engaging in sexual intercourse with a female partner who could&#xD;
             become pregnant. This criterion must be followed from the time of the first dose of&#xD;
             study medication until 84 days after the last dose of study medication&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  History of other than rare (once yearly or less) flushing, particularly in&#xD;
             perimenopausal women&#xD;
&#xD;
          -  A hemoglobin A1c above the normal reference range and/or fasting blood glucose ≥100&#xD;
             mg/dL at the screening visit&#xD;
&#xD;
          -  History of intra-ocular pathology, including but not limited to retinitis, uveitis,&#xD;
             retinal detachment and macular edema&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>October 29, 2007</study_first_submitted>
  <study_first_submitted_qc>October 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2007</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK256073A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

